Pittsburgh, PA (PRWEB) February 25, 2013
Liquid medication taken under the tongue is a safe and effective alternative to injections for ragweed allergy sufferers, according to a study presented today at the annual meeting of the American Academy of Asthma, Allergy and Immunology in San Antonio, TX.
The study is the first Phase III clinical trial to demonstrate the efficacy of liquid sublingual therapy for ragweed allergy, North America’s dominant seasonal allergy.
Deborah Gentile, MD, Director of Research in the Division of Allergy, Asthma and Immunology at Allegheny General Hospital and one of the lead authors on the study, said the results are great news for allergy patients, who could soon find weekly visits to the doctor’s office for allergy shots becoming a thing of the past.
“With sublingual immunotherapy, allergy patients can administer their own medication at their convenience, without leaving their homes,” Dr. Gentile said. “We also expect more patients will adhere to their medication regimen when no injections are involved.”
Dr. Gentile collaborated in the study with Peter S. Creticos, MD of Creticos Research Group, Crownsville, Maryland and Allergy and Asthma Specialists of Greater Washington, Warrenton, Va.; Robert Esch, Ph.D., and Brad Whitlow, BS, of Greer Laboratories, Lenoir, NC; Peter Couroux, MD, Topstone Research, Toronto, Ont; Pina D’Angelo, M.Sc., PRACS Institute, Mississauga, Ont., and Michael Alexander, MD of Niagara Clinical Research, Niagara Falls, Ont.
A successful Phase 3 clinical trial marks the
Copyright©2012 Vocus, Inc.
All rights reserved